Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BMY stock price vs PACB: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at PACB's multiple
Needs PACB P/E.
Implied fair value · at BMY's multiple
Needs Annual EPS is negative, BMY P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BRISTOL-MYERS SQUIBB COMPANY · implied price per share
Bear
$50.67
Base
$61.69
Bull
$77.14
Pacific Biosciences of California, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
BMY vs PFE
Merck & Co., Inc.
BMY vs MRK
AbbVie Inc.
BMY vs ABBV
Eli Lilly and Company
BMY vs LLY
Amgen Inc.
BMY vs AMGN
Gilead Sciences, Inc.
BMY vs GILD
ILLUMINA, INC.
BMY vs ILMN
THERMO FISHER SCIENTIFIC INC.
BMY vs TMO
AGILENT TECHNOLOGIES, INC.
BMY vs A
DANAHER CORP /DE/
BMY vs DHR
REVVITY, INC.
BMY vs RVTY
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BMY’s current profitability and balance sheet quality should be valued closer to its historical and DCF midpoint than the PACB-based comparison implies, then hold or modestly accumulate BMY because PACB-based downside is only -1.5% and the business fundamentals are far stronger than PACB’s.
The current price of $65.31 is essentially in line with the implied price of $64.32, indicating only a -1.5% downside versus PACB-based valuation. On the provided P/S basis, BMY and PACB are close at 2.8x and 2.7x, but the market is pricing very different business quality beneath that similarity.
Supporting Metrics
